@FierceMedDev: We've compiled the 15 fiercest med tech companies. Check out FierceMedicalDevices' Fierce 15. Special Report | Follow @FierceMedDev
@MichaelGFierce: RT @EmilyMFierce: Did you miss our list of notable academic-pharma alliances of 2014? Check it out here. Report from FierceBiotechResearch | Follow @MichaelGFierce
@VarunSaxena2: Med tech attorneys say FDA ramping up monitoring of device promotion. Editor's Corner | Follow @VarunSaxena2
@EmilyWFierce: Babies tune out sounds that don't exist in mother's native tongue, form "library of sounds" in brain. Story from Wired | Follow @EmilyWFierce
> Here's a running tally of the health apps compatible with the newly launched Apple's ($AAPL) HealthKit. List
> Freezing benign breast tumors takes 6 minutes and is half the cost of surgery. The technology comes from Israeli-made IceSense3, by IceCure Medical, and is currently in clinical testing. More
> Rapid diagnostics company Alere ($ALR) signed a 3.5 year contract with the U.S. Department of Health and Human Services to receive up to $12.9 million to develop a rapid, molecular, low-cost influenza diagnostic device. Release
> A 5-year, $17 million research collaboration was announced between University of California, San Francisco, other universities, General Electric ($GE) and government agencies including the Defense Department. Researchers will work on boosting methods of conducting clinical trials aimed at new drugs and medical devices for traumatic brain injuries. Story
Biotech News
@FierceBiotech: Hemispherx to test FDA-rejected drug, other candidates against Ebola. FierceBiotech Research story | Follow @FierceBiotech
@JohnCFierce: Baxter inks a big lease in the heart of Cambridge for biopharma R&D headquarters - (more for hubs, less for Chicago). More | Follow @JohnCFierce
@DamianFierce: And now the @FierceMedDev Fierce 15, featuring therapeutic apps, next-gen valves and a light-based hearing aid. Report from FierceMedicalDevices | Follow @DamianFierce
@EmilyMFierce: Global Survey Says We're Eating Better, But Our Diet Is Still Unsustainable. National Geographic story | Follow @EmilyMFierce
> Novartis drops out of hep C race, punting a $440M Enanta pact. More
> FibroGen lines up a $125M IPO to shoulder its way into the IPF race. Story
> AstraZeneca partner Ardelyx scores a trial success for GI drug. News
> Portola's 'breakthrough' anti-anticoagulant clears a Phase III hurdle. Article
Pharma News
@FiercePharma: Report: Indian government to take legal action over drug quality paper. FiercePharmaManufacturing item | Follow @FiercePharma
@TracyStaton: ICYMI: Who are the fiercest companies in biotech these days? Check out @FierceBiotech's latest Fierce 15. Special Report | Follow @TracyStaton
@CarlyHFierce: Pfizer DTC message: Hey guys, women say it's cool to take Viagra. Story via FiercePharmaMarketing | Follow @CarlyHFierce
> Orphan drugs may be pricey, but payers are barely balking. Article
> FDA slaps Valeant with a warning letter. Will Allergan slap it, too? More
Drug Delivery News
> Projection: Implantable drug delivery market to reach $21.1B by 2018. Item
> Which vehicle works best? High-speed testing gives drug delivery a boost. Story
> Alnylam launches study to support its rare disease candidate ALN-AS1. More
> Allergan's drug-delivering eye implant gets expanded indication from FDA. News
> Detoxified anthrax used to deliver cancer drugs within cells. Article
Diagnostics News
> Thermo Fisher has made universal companion Dx development an official trend. Report
> Autism diagnosis could become clearer with sound/sight response screening. More
> Japan approves Infraredx's intravascular ultrasound Dx imaging device. Article
> Trinity Biotech expects FDA submission in early 2015 for heart failure Dx. Story
> J&J, others join $6.5M funding round for U.K. liquid biopsy company. Item
Pharma Marketing News
> Pfizer DTC message: Hey guys, women say it's cool to take Viagra. Story
> Survey: No need to worry about sky-high prices for orphan drugs. Item
> Sunshine fact: $3.5B + 546,000 docs equals one unwieldy database. Report
> Sucampo's Amitiza targets 45-plus women with belly-as-balloon DTC ads. Article